BC Extra | Aug 27, 2019
Company News

Aug. 27 Company Quick Takes: GSK licenses Ionis HBV program; plus Adaptimmune-Noile, Purdue, Presage-BMS, Kyowa, Alexion, Viela, Kintai, OncoNano

GSK opts into Ionis' HBV program  Positive Phase II data prompted GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to exercise its option to license exclusive, worldwide rights to an antisense chronic HBV program from Ionis Pharmaceuticals Inc. (NASDAQ:IONS)....
BC Week In Review | Mar 3, 2017
Clinical News

ND0612H: Preliminary Ph IIa Trial 006 data

Preliminary data from the observer-blind, international Phase IIa Trial 006 in 38 advanced PD patients showed that continuous 24-hour treatment with ND0612H met the primary endpoint of reducing daily “off” time vs. baseline (2.7 vs....
BC Extra | Mar 2, 2017
Clinical News

NeuroDerm rises on Phase IIa PD readout, new EU path

NeuroDerm Ltd. (NASDAQ:NDRM) gained $6.15 to $29.30 on Wednesday after it said ND0612H met the primary endpoint in the Phase IIa Trial 006 to treat advanced Parkinson’s disease. The company also revealed a new European...
BC Week In Review | Jul 11, 2016
Clinical News

Levodopa/carbidopa: Phase I data

Top-line data from the open-label, crossover, U.K. Phase I ND0612-005 trial in 36 healthy volunteers showed that subcutaneous ND0612H achieved a “comparable” pharmacokinetic profile to that of intraduodenal Duopa levodopa/carbidopa intestinal gel. No safety or...
BC Week In Review | Jan 4, 2016
Clinical News

ND0612H: Phase IIa started

NeuroDerm began the observer-blind, international Phase IIa ND0612H-006 trial to compare 2 dosing regimens of continuous subcutaneous infusion of ND0612H over 14 or 24 hours vs. the baseline oral standard of care (SOC) in about...
BC Week In Review | Nov 9, 2015
Clinical News

LECIGon: Phase I data

An open-label, crossover, Swedish Phase I trial in 11 PD patients showed that LECIGon met the primary bioavailability endpoint vs. Duodopa carbidopa/levodopa. Specifically, LECIGon led to a 38% increase in levodopa bioavailability during daytime enteral...
BC Week In Review | Jun 22, 2015
Clinical News

ND0612H: Phase I started

NeuroDerm began an open-label, dose-finding, U.K. Phase I trial to compare single doses of subcutaneous ND0612H vs. Duopa carbidopa/levodopa intestinal gel in about 24 healthy volunteers. NeuroDerm Ltd. (NASDAQ:NDRM), Ness Ziona, Israel   Product: ND0612H...
BC Week In Review | Feb 9, 2015
Clinical News

Duopa carbidopa/levodopa regulatory update

FDA approved an NDA from AbbVie for Duopa carbidopa/levodopa to treat motor fluctuations in patients with advanced Parkinson’s disease. The levodopa-carbidopa intestinal gel is approved in 41 countries, including those in the EU, Australia, Canada...
BioCentury | Oct 1, 2012

3Q Stock Wrap-Up: Back in black

Large cap biotechs stormed back after a weak 2Q12 to post a 7% gain for a third quarter in which every market cap segment finished in the black, albeit just barely for the micro-caps. For...
BC Week In Review | May 7, 2012
Clinical News

Duodopa levodopa/carbidopa: Phase III data

A double-blind, international Phase III trial in 71 patients with advanced PD and severe motor fluctuations showed that Duodopa met the primary endpoint of reducing mean daily "off" time in which patients experienced symptoms of...
Items per page:
1 - 10 of 19